MARAMPON, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 1.115
EU - Europa 776
AS - Asia 153
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 2.051
Nazione #
US - Stati Uniti d'America 1.111
IE - Irlanda 347
CN - Cina 112
DE - Germania 86
IT - Italia 79
SE - Svezia 79
BE - Belgio 74
UA - Ucraina 45
GB - Regno Unito 33
TR - Turchia 31
FR - Francia 15
VN - Vietnam 7
FI - Finlandia 6
AU - Australia 3
CA - Canada 3
EU - Europa 3
NL - Olanda 2
PT - Portogallo 2
RU - Federazione Russa 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
ES - Italia 1
IL - Israele 1
IN - India 1
JP - Giappone 1
PA - Panama 1
PL - Polonia 1
RO - Romania 1
Totale 2.051
Città #
Dublin 343
Chandler 306
Jacksonville 183
Brussels 74
Ann Arbor 63
Ashburn 57
New York 52
Lawrence 34
Princeton 34
Wilmington 34
L'aquila 33
Bremen 32
Beijing 27
Nanjing 27
Izmir 24
Woodbridge 16
Boardman 15
San Mateo 15
Falls Church 12
Grafing 12
Des Moines 10
Seattle 9
Shenyang 9
Washington 9
Cambridge 8
Mountain View 8
Dearborn 7
L’Aquila 7
Milan 7
Changsha 6
Dong Ket 6
Hebei 6
Nanchang 6
Norwalk 6
Kunming 5
Tianjin 5
Hanover 4
Napoli 4
Zhengzhou 4
Houston 3
Jinan 3
Shanghai 3
Tappahannock 3
Verona 3
Bolton 2
Braga 2
Fremont 2
Guangzhou 2
Jiaxing 2
Lanzhou 2
Menlo Park 2
Ningbo 2
Piombino Dese 2
Redwood City 2
Rome 2
Saint Paul 2
Toronto 2
Vittuone 2
Adliswil 1
Amsterdam 1
Beauharnois 1
Bellante 1
Canberra 1
Carlentini 1
Cedar Knolls 1
Cormeilles-en-Parisis 1
Detroit 1
Edinburgh 1
Fairfield 1
Frankfurt am Main 1
Gainesville 1
Gold Hill 1
Groningen 1
Hanoi 1
Irkutsk 1
Lodi 1
Logan 1
Madrid 1
Moscow 1
Nanning 1
Panama City 1
Pune 1
San Diego 1
Sydney 1
Taizhou 1
Tel Aviv 1
Teramo 1
Tokyo 1
Vienna 1
Villeneuve 1
Warsaw 1
Totale 1.595
Nome #
Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgenindependent prostate cancer cells to DNA damage 105
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma 95
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma 94
Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells 90
Distinctive binding properties of the negative allosteric modulator, [3H]SB269,652, at recombinant dopamine D3receptors 86
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models 80
Vitamin D protects endothelial cells from irradiation-induced senescence and apoptosis by modulating MAPK/SirT1 axis 75
The possible prognostic role of histone deacetylase and transforming growth factor β/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study 74
Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: A retrospective study by propensity analysis 73
Neurotoxic and Neuroprotective Role of Exosomes in Parkinson's Disease 73
Dichlorodiphenyltrichloroethane, an old pesticide with a new mechanism of toxicity 70
Clinically relevant radioresistant rhabdomyosarcoma cell lines: Functional, molecular and immune-related characterization 70
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models 64
Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results 64
The brain penetrating and dual TORC1/TORC2 inhibitor, RES529, elicits anti-glioma activity and enhances the therapeutic effects of anti-angiogenetic compounds in preclinical murine models 62
The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models 59
The First Negative Allosteric Modulator for Dopamine D2and D3Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs 58
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma 58
Correction: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma (Journal of Hematology and Oncology (2018) 11(32) DOI: 10.1186/s13045-018-0576-6) 57
Sulodexide counteracts endothelial dysfunction induced by metabolic or non-metabolic stresses through activation of the autophagic program 57
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma (Journal of Cancer Research and Clinical Oncology, (2019), 145, 2, (393-409), 10.1007/s00432-018-2800-8) 57
A New Threat to Dopamine Neurons: The Downside of Artificial Light 53
Parkinson's disease and light: The bright and the Dark sides 49
Allosteric modulators of g protein-coupled dopamine and serotonin receptors: A new class of atypical antipsychotics 47
Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell Lines in Vitro and in Vivo 47
Pro-differentiating and radiosensitizing effects of inhibiting HDACs by PXD-101 (Belinostat) in in vitro and in vivo models of human rhabdomyosarcoma cell lines 45
Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo 43
ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma 43
Are we ready for a paradigm shift from high-dose conventional to moderate hypofractionated radiotherapy in intermediate-high risk prostate cancer? A systematic review of randomized controlled trials with trial sequential analysis 42
Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation 39
The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma 38
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma 36
Ms−275 (Entinostat) promotes radio-sensitivity in pax3-foxo1 rhabdomyosarcoma cells 36
Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype 33
Radioresistance Mechanisms in Prostate Cancer Cell Lines Surviving Ultra-Hypo-Fractionated EBRT: Implications and Possible Clinical Applications 22
Interaction of the preferential D3 agonist (+)PHNO with dopamine D3-D2 receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging 18
Totale 2.112
Categoria #
all - tutte 7.238
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.238


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201961 0 0 0 0 0 0 0 0 4 13 2 42
2019/2020224 37 1 19 4 3 39 40 4 30 17 5 25
2020/2021267 5 27 11 27 27 9 36 2 43 12 52 16
2021/2022249 11 2 38 12 12 21 9 7 36 20 15 66
2022/2023898 49 69 12 124 61 85 2 49 402 9 24 12
2023/2024237 21 15 18 42 23 94 12 12 0 0 0 0
Totale 2.112